Impact of the Extended Thrombolysis Time Window on the Proportion of Recombinant Tissue-Type Plasminogen Activator-Treated Stroke Patients and on Door-to-Needle Time | Zendy

Jens Minnerup | Zendy; Heike Wersching | Zendy; E. Bernd Ringelstein | Zendy; Matthias Schilling | Zendy; WolfRüdiger Schäbitz | Zendy; Jürgen Wellmann | Zendy; Klaus Berger | Zendy

Open Access

Impact of the Extended Thrombolysis Time Window on the Proportion of Recombinant Tissue-Type Plasminogen Activator-Treated Stroke Patients and on Door-to-Needle Time

Author(s) -

Jens Minnerup,

Heike Wersching,

E. Bernd Ringelstein,

Matthias Schilling,

WolfRüdiger Schäbitz,

Jürgen Wellmann,

Klaus Berger

Publication year - 2011

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.111.616565

Subject(s) - medicine , thrombolysis , stroke (engine) , plasminogen activator , tissue plasminogen activator , recombinant tissue plasminogen activator , acute stroke , surgery , prospective cohort study , ischemic stroke , ischemia , modified rankin scale , myocardial infarction , mechanical engineering , engineering

The European Cooperative Acute Stroke Study (ECASS) III extended the thrombolysis time window for patients with stroke from 3 to 4.5 hours after symptom onset. We investigated the effect of the extended thrombolysis time window on the proportion of recombinant tissue-type plasminogen activator-treated stroke patients and on the time of treatment initiation after hospital arrival.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research